O-300 Dydrogesterone versus GnRH-antagonists to supress the LH surge in IVF/ICSI cycles

Abstract

Abstract Study question Does Dydrogesterone block premature Luteinaizing hormone surge and ovulation during the controlled ovarian stimulation without compromising of IVF/ICSI outcomes? Summary answer Dydrogesterone and GnRH-antagonist have equal effectivness for prevention of premature luteinizing hormone surge and ovulation without any adverse effect on laboratory and clinical results. What is known already Premature LH surge and premature ovulation during the controlled ovarian stimulation is one of the main causes of cycle cancellation.Traditionally, during in-vitro fertilization for controlled ovarian stimulation to prevention of premature LH surge clinicians use GnRH antagonists. Recent data indicates that premature LH surge may be prevented also by progestins, since they have a role in suppression of preovulatory LH surge. In past, progesterone was not used during ovarian stimulation due to the negative effect on endometrial receptivity, while nowadays advanced techniques give possibility to use it as an alternative to a GnRH antagonists using the freeze-all strategy. Study design, size, duration In this prospective, randomized study were participated sixty -seven egg donors. Sudy was conducted on the basis of Clinic Leadermed (Georgia, Tbilisi) from October of 2021 to November 2023. The Ethics Committee of clinic Leadermed approved this study and appropriate informed consent was obtained from all participants. Participants/materials, setting, methods Recombinant gonadotropin was administered for control ovulation stimulation in oocyte donors. According to the ovarian response HMG was added. Intervention group (group I, n = 34) received 20 mg of Dydrogesterone from the first day of stimulation till trigger day and the control group (group II, n = 33) received GnRH-antagonist when the leading follicle reached 14 mm in diameter till trigger day. Triptorelin acetate 0.3 mg was administered when at least 3 follicles reached ≥18 mm in diameter. Main results and the role of chance There were no statistically significant differences in the oocyte donors age, BMI and AMH levels between two groups. None of the participants experienced a premature LH surge and ovulation. There was no statistically significant difference in the number of MII oocytes (23,7 vs 25.9 p = 0.3). The duration of stimulation and total dose of gonadotropins was similar in both groups (9.6 vs 9.9 days, p = 0.41), (2269.2 IU vs 2423.4 IU, p = 0.08) respectively. There was no difference in fertilization rates (85.62% vs 83.94%, p = 0.41), as well as blastulation rates and top-quality blastocysts (65.78% vs 69.72%, p = 0.17; 54.50% vs 51.75%, p = 0.21). Regarding clinical pregnancy rate, the results were similar, with no significant differences between two groups (66.28% vs 68.10%, p = 0.8). Limitations, reasons for caution The limitation of the study is that embryotransfer was performed as in patients (age till 49years), as well as in surrogate mothetrs (age till 41 years). Wider implications of the findings Dydrogesterone and GnRH-antagonist has equal effectiveness for prevention of premature LH surge without affecting of IVF outcomes. It is a financially profitable and easy to use which can be used as in oocyte donors as well as in patients where embryo transfer is not planned in the current cycle. Trial registration number non-clinical trial